With the rapid advancements in cell and gene therapy, particularly in cancer and vaccine research, selecting an effective delivery system for DNA has become a crucial aspect of therapeutic development. DNA vaccines offer significant advantages, including high safety, ease of production, and cost-effectiveness, with promising applications in infectious diseases and cancer treatment. CD Formulation leverages advanced liposome encapsulation technology to develop stable plasmid DNA-encapsulated liposomes, tailored to meet the needs of researchers and pharmaceutical companies. Our innovative solutions aim to support the progress of cutting-edge DNA-based therapeutic research and development.
In comparison to earlier transfection protocols, liposomes and liposome-based complexes signify a substantial advancement in encapsulation technology, offering a promising foundation for the design of nanoparticles with transfection capabilities through the strategic incorporation of targeting elements.
Fig.1 The illustration of liposome delivery for plasmid DNA. (Bellefroid C, et al, 2021)
The construction of plasmid vectors is a critical aspect of genetic engineering, essential for inserting target genes into plasmids. Its success directly impacts the progression of genetic research. Therefore, we will carefully control each step and validate every detail throughout the process.
Our services range from formulation development studies in the small pilot phase of liposomes to process optimization. In the pilot phase, we conduct a variety of experiments to determine the optimal composition ratio and preparation conditions. This process includes not only the evaluation of different liposomal materials and their interactions, but also a systematic analysis of drug loading capacity, release properties, and stability. In addition, in process optimization, we will constantly adjust the parameters based on the preliminary experimental results to improve production efficiency and reduce costs.
The most important thing for liposome transfection is to prevent its toxicity. Therefore, the ratio of liposome to plasmid, cell density, length of transfection time, and serum content in the medium are all important issues that affect transfection efficiency. We explore suitable transfection conditions through experiments to improve the transfection efficiency.
We provide quality control services for liposomes. Test indicators include but not are limited to:
Techniques and Platforms | Specifics |
Plasmid DNA Construction Platform |
|
Plasmid DNA Encapsulation Technology |
|
Characterization Platform |
|
Plasmid DNA Construction Platform
A Premier Liposome Encapsulation Platform for Plasmid DNA
Top Teams
Technology: Arginine-modified chitosan liposome systems technique
Journal: Colloids and Surfaces B: Biointerfaces
IF: 6.6
Published: 2020
Results: In this study, a chitosan-based carrier (chitosan carrier) was synthesized by a reverse evaporation method modified by arginine, and composed of chitosan, DOTAP/DOPE lipid complex. The structure of the chitosan carrier containing or not containing pDNA was analyzed by electrophoresis, zeta potential, dynamic light scattering, small-angle X-ray scattering, and isothermal titration calorimetry. The transfection efficiency and cytotoxicity were studied in HEK293 T cells. The results showed that the synthesized chitosan was a promising carrier for gene delivery.
Fig.2 Arginine-modified chitosan complexed with liposome systems for plasmid DNA delivery. (Garcia BB, et al., 2020)
CD Formulation specializes in offering advanced liposome encapsulation technology for plasmid DNA, designed to meet the specific needs of pharmaceutical companies and researchers. Our innovative solutions ensure stability and efficiency, supporting cutting-edge research and development in gene therapy, vaccine development, and other DNA-based applications. Contact us to learn how we can assist with your scientific projects.
References